Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
66 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Sorrento Therapeutics, Inc. (STI), formerly QuikByte Software, Inc., which develops novel treatments for cancer, inflammation and autoimmune diseases. It discovers small molecules, antibody drug conjugates, and antibodies for the treatment of cancer and its associated pain. Its pipeline products include mAbs, CAR-T, CAR.TNK and resiniferatoxin. STIs product Cynviloq is a novel nanoparticle formulation of paclitaxel, is used for the treatment of metastatic breast cancer, pancreatic cancer and non-small cell lung cancer. The company works in collaboration with biopharmaceutical companies and academic institutions to develop the novel immunotherapies.

Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

  
Source:
Document ID
GDPH185554D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables42
  List of Figures61
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201662
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201681
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201691
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 2016101
Sorrento Therapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016111
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016123
Sorrento Therapeutics, Inc., Pharmaceuticals &Healthcare, Deal Details1548
  Asset Purchase151
    Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma151
    Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma162
    Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma182
    Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins201
  Partnerships211
    Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies211
    Sorrento Therapeutics to Form Joint Venture with CHA Biotech221
    TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma231
    Sorrento Therapeutics to Form Joint Venture with Yuhan241
    Sorrento Therapeutics Enters into Partnership with Karolinska Institutet251
    Sorrento Therapeutics and NantBioscience Form Joint Venture261
    Advaxis Enters into Research Agreement with Sorrento Therapeutics271
    Sorrento Therapeutics Enters into Co-Development Agreement with Conkwest281
    NantWorks to Form Joint Venture with Sorrento Therapeutics291
    Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek301
    Sorrento Therapeutics Enters Into Co-Development Agreement With The Scripps Research Institute311
  Licensing Agreements321
    Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics322
    Sorrento Therapeutics Enters into Licensing Agreement with City of Hope341
    Sorrento Therapeutics Enters into Licensing Agreement with Mabtech351
    Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences361
    NantWorks to Enter into Licensing Agreement with Sorrento Therapeutics371
    Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody382
    Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute401
    Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System411
    Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones421
  Equity Offering431
    Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants432
    Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants452
    Sorrento Therapeutics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares472
    Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million492
    Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million511
    Sorrento Therapeutics Completes Private Placement Of Shares For US$2 Million521
  Acquisition531
    Scintilla Pharma to Acquire Semnur Pharma531
    Scintilla Pharma to Acquire Scilex Pharma for Up to USD70 Million542
    TNK Therapeutics Acquires Two Biotechnology Companies561
    NantPharma Acquires IgDraSol from Sorrento Therapeutics571
    NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million581
    Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million591
    Sorrento Acquires Sherrington, Chronic Pain Therapies Provider601
    Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million612
Sorrento Therapeutics, Inc. - Key Competitors631
Key Employees641
Locations And Subsidiaries651
  Head Office651
  Other Locations &Subsidiaries651
Appendix661
  Methodology661
  About GlobalData661
  Contact Us661
  Disclaimer661

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sorrento-Therapeutics-Inc-SRNE-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-10422>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sorrento-Therapeutics-Inc-SRNE-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-10422>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research